Expert Opinion on Drug Metabolism & Toxicology

Article	Citations
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer	87
Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity	74
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion	55
High-throughput PBTK models for in vitro to in vivo extrapolation	49
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?	46
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study	44
Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: should there be a critical screening parameter in drug designing protocols?	44
The pharmacokinetics of antibiotics in cystic fibrosis	40
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity	40
Alterations in drug disposition in older adults: a focus on geriatric syndromes	39
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advancedin vitrotesting	38
Drug metabolism in the lungs: opportunities for optimising inhaled medicines	35
Tumor grafted – chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation	34
Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems	33
Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs	29
SULT genetic polymorphisms: physiological, pharmacological and clinical implications	27
Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization	27
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?	26
Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder	26
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies	25
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	25
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review	24
Genetic risk factors in the development of idiosyncratic drug-induced liver injury	22
Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease	20
GenotypingHLAalleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art	19

An update on the use of inositols in preventing gestational diabetes mellitus (GDM) and neural tube defects (NTDs)	19
A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients	18
Renal and non-renal response of ABC and SLC transporters in chronic kidney disease	17
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	17
Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity	17
Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion	17
Genetic factors influencing the development of vincristine-induced neurotoxicity	16
Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials	16
Drug-drug interactions between psychotropic medications and oral contraceptives	16
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia	16
Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse	15
Novel test strategies for in vitro seizure liability assessment	15
Pharmacogenomics in Asians: Differences and similarities with other human populations	15
An update on drug–drug interactions associated with proton pump inhibitors	15
The role of cytochrome P450 (CYP) enzymes in hyperoxic lung injury	15
Coffee in cancer chemoprevention: an updated review	14
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis	14
Circadian regulation of transporter expression and implications for drug disposition	14
Assessing the pharmacokinetics and toxicology of polymeric micelle conjugated therapeutics	14
The regulation of liver cytochrome P450 expression and activity by the brain serotonergic system in different experimental models	13
Xanthones as P-glycoprotein modulators and their impact on drug bioavailability	13
Evolving approaches on measurements and applications of intracellular free drug concentration and Kpuu in drug discovery	13
Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjec	13
Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it	13
Evaluating the risk of manganese-induced neurotoxicity of parenteral nutrition: review of the current literature	13
An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables	12
Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs	12
Inositols in the ovaries: activities and potential therapeutic applications	12
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia	12
Novel models for the prediction of drug–gene interactions	12
Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism	12
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships	12
Xanthones from Securidaca inappendiculata antagonized the antirheumatic effects of methotrexate in vivo by promoting its secretion into urine.	12
Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management	12
Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review	11
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature	11
Positioning the new drugs for migraine	11
Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy	11
Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs	11
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature	11
Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions	10
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	10
Machine learning models in the prediction of drug metabolism: challenges and future perspectives	10
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice	10
Modeling drug transport within the viable skin - a review	10
A review on the clinical pharmacokinetics of hydralazine	9
Restoration and stabilization of acrylamide-induced DNA, mitochondrial damages and oxidative stress by chrysin in human lymphocyte	9
Exposure to antibiotics during pregnancy alters offspring outcomes	9
The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV	9
The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions	9

Modeling drug-induced liver injury: current status and future prospects	9
Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated	9
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence	9
Toward regulatory acceptance and improving the prediction confidence of in silico approaches: a case study of genotoxicity	9
Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties	9
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more	9
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	9
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	8
A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database	8
CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia	8
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	8
The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients	8
AMPK activators for the prevention and treatment of neurodegenerative diseases	8
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis	8
Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies	8
Refining in vitro and in silico neurotoxicity approaches by accounting for interspecies and interindividual differences in toxicodynamics	7
Pharmacokinetics and pharmacodynamics of direct oral anticoagulants	7
Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties	7
Inhibition effect of epigallocatechin-3-gallate on the pharmacokinetics of calcineurin inhibitors, tacrolimus, and cyclosporine A, in rats	7
An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies	7
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	7
A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer	7
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment	7
An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease	7
A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy	7
A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers	7
Strategies for enhancing the oral bioavailability of cannabinoids	6
Are we still on the right path(way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy	6
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	6
Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates	6
Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics	6
Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: part 2. development of oral dosage formulations	6
Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors	6
Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects	6
Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis	6
Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug–drug interaction in healthy adults and its extrapolation to virtual chronic	6
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics	5
Evaluating the risk of toxicity and adverse drug interactions involving recreational GHB use and prescribed drugs	5
Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs	5
Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations	5
Individualizing doses of antiepileptic drugs	5
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs	5
Recent lessons learned from population pharmacokinetic studies of mycophenolic acid: physiological, genomic, and drug interactions leading to the prediction of drug effects	5
Local anesthetics and erector spinae plane blocks: a spotlight on pharmacokinetic considerations and toxicity risks	5
Biology and therapeutic applications of the proton-coupled folate transporter	5
Ceftazidime dosing in obese patients: is it time for more?	5
Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development	5
Absorption, distribution, metabolism and excretion of hyaluronic acid during pregnancy: a matter of molecular weight	5
Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review	5
Where developmental toxicity meets explainable artificial intelligence: state-of-the-art and perspectives	5
Organotypic-liver slide culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approaches	5
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach	5
Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units	5
Managing intoxications with nicotine-containing e-liquids	5
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies	5
Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties	5
Adverse events related to drug–drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review	5
Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients	5
Common gastrointestinal drug-drug interactions in geriatrics and the importance of careful planning	5
Strategies for the treatment of acute benzodiazepine toxicity in a clinical setting: the role of antidotes	4
Drug–drug interactions involving antipsychotics and antihypertensives	4
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	4
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition	4
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	4
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia	4
Comorbidities and the right dose: antipsychotics	4
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data	4
Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens	4
Recent advances in cell-based in vitro models for predicting drug permeability across brain, intestinal, and pulmonary barriers	4
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	4
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	4
Prescription of statins and pharmacokinetic interactions in Colombian patients	4
The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions	4
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults	4
Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction	4
Genetic variation in organic cation transporters and considerations in drug development	4
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration	4
Pharmacokinetics during therapeutic hypothermia in neonates: from pathophysiology to translational knowledge and physiologically-based pharmacokinetic (PBPK) modeling	4
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	4
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease	4

Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics	4
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study	4
Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment	3
Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions	3
The impact of advanced age on anticoagulant therapy for acute venous thromboembolism	3
Can dantrolene be used in the treatment of cardioglycosides poisonings?	3
Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems	3
What might the presence of ‘orphan’ CYP450 isoforms in breast epithelial cells mean for the future of targeted therapeutics?	3
The impact ofcatha edulis (vahl) forssk. ex endl. (celestraceae) (khat) on pharmacokinetics of clinically used drugs	3
Comparing the pharmacokinetics of extended-release tacrolimus (LCP-TAC) to immediate-release formulations in kidney transplant patients	3
Current strategies for predicting side effects from second generation antipsychotics in youth	3
The influence of cardiopulmonary bypass on pediatric pharmacokinetics	3
The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)	3
Therapeutic drug monitoring in developing nations: assessing the current state of affairs in South America	3
The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics	3
Cardiomyocyte-specific CYP2J2 and its therapeutic implications	3
Overcoming barriers to machine learning applications in toxicity prediction	3
What is the significance of the pharmacokinetic profile and potential drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine?	3
A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens	3
The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review	3
Advances in the understanding of acetaminophen toxicity mechanisms: a clinical toxicology perspective	3
Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations	3
New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact	2
Lessons learned from the influence of CYP2C9 genotype on warfarin dosing	2
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer	2
Considerations for laxatives in terms of their interactions with other drugs	2
Drug–drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs	2
Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview	2
What is the significance of the impact of antipsychotics on the gut microbiome?	2
Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants	2
Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients	2
Safety of medicines during breastfeeding – from case report to modeling: a contribution from the ConcePTION project	2
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	2
A comprehensive update on the ADMET considerations for α2δ calcium channel ligand medications for treating restless legs syndrome	2
Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview	2
Ceftriaxone and methicillin-susceptible staphylococcus aureus: a perspective from pharmacokinetics/pharmacodynamics studies	2
Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research	2
Current status and future outlooks on therapeutic drug monitoring of fluorouracil	2
Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity	2
A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation	2
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	2
Guidance for interactions between antiseizure medications	2
Probing the mechanism of reduced in vivo potency of insulin detemir	2
Pharmacokinetic and pharmacodynamic evaluation of the new prolonged-release leuprorelin acetate microspheres for injection compared with Enantone® in healthy Chinese male volunteers	2
Drug interactions of carbonic anhydrase inhibitors and activators	2
Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder	2
The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review	2
Potential drug–drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma	2
Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook	2
What is the most effective and safest Non-steroidal anti-inflammatory drug for treating osteoarthritis in patients with comorbidities?	2
Drug-induced liver injury associated with the use of newer antiseizure medications in the elderly: an analysis of data from VigiBase	2
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	2
Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine	2
Review and evaluation of vancomycin dosing guidelines for obese individuals	2
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling	2